Versant Venture Management Lowers stake in Glaukos Corp (GKOS)

Glaukos Corp (GKOS) : Versant Venture Management reduced its stake in Glaukos Corp by 90.2% during the most recent quarter end. The investment management company now holds a total of 3,136,232 shares of Glaukos Corp which is valued at $59,086,611 after selling 28,880,405 shares in Glaukos Corp , the firm said in a disclosure report filed with the SEC on Apr 25, 2016.Glaukos Corp makes up approximately 37.36% of Versant Venture Management’s portfolio.

Glaukos Corp opened for trading at $19.37 and hit $19.99 on the upside on Monday, eventually ending the session at $19.78, with a gain of 4.99% or 0.94 points. The heightened volatility saw the trading volume jump to 5,46,734 shares. Company has a market cap of $640 M.

Other Hedge Funds, Including , Metlife Securities Inc reduced its stake in GKOS by selling 100 shares or 50.0% in the most recent quarter. The Hedge Fund company now holds 100 shares of GKOS which is valued at $1,845.Bnp Paribas Arbitrage Sa reduced its stake in GKOS by selling 598 shares or 76.77% in the most recent quarter. The Hedge Fund company now holds 181 shares of GKOS which is valued at $3,339. Strs Ohio sold out all of its stake in GKOS during the most recent quarter. The investment firm sold 2,200 shares of GKOS which is valued $40,590. Hamilton Lane Advisors added GKOS to its portfolio by purchasing 40,220 company shares during the most recent quarter which is valued at $746,081. Glaukos Corp makes up approx 0.35% of Hamilton Lane Advisors’s portfolio.

On the company’s financial health, Glaukos Corp reported $-0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Mar 1, 2016. Analyst had a consensus of $-0.12. The company had revenue of $20.28 million for the quarter, compared to analysts expectations of $20.07 million. The company’s revenue was up 43.7% compared to the same quarter last year.

Many Wall Street Analysts have commented on Glaukos Corp. Glaukos Corp was Initiated by Stifel to “Hold” on Apr 8, 2016. Piper Jaffray Initiated Glaukos Corp on Feb 9, 2016 to “Overweight”, Price Target of the shares are set at $19.

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies including three pipeline products namely the iStent Inject the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Leave a Reply

Glaukos Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Glaukos Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.